Arca
Skip to content
Tools
Tools

Hemodialysis

Drug research and approvals for hemodialysis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 180 studies of hemodialysis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 2 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 180
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 180 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 15, 2025Glucagon-like-peptide-1 receptor agonists in patients receiving maintenance dialysisOzempicUnity Health TorontoOngoing
Jan 9, 2019Dialysis symptom control-restless legs syndrome trial (disco-rls trial)Ropinirole/ GabapentinHamilton Health Sciences CorporationClosed
Dec 17, 2018Effectiveness of ropinirole and gabapentin for the treatment of restless legs syndrome in patients on maintenance hemodialysis: a randomized, blinded,…Gabapentin / RopiniroleGovernors of The University of AlbertaClosed
Feb 19, 2016Pharmacokinetics and pharmacodynamics of apixaban in end-stage renal disease patients on hemodialysisApixabanJewish General HospitalClosed
Sep 3, 2014Dose-ranging, parallel-group, randomized controlled trial of long-term ferumoxytol dosage strategies in hemodialysis patientsFerumoxytolDr François MadorePending

FDA orphan designations

Approved first, then open designations, newest first
Oct 23, 2025Dehydrated alcoholTreatment of methanol poisoning in combination with hemodialysis in adultsBE Pharmaceuticals, LLCApproved
Dec 8, 2000AntizoleUse for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysisPar Pharmaceuticals, IncApproved
Jun 15, 2017Human monoclonal antibody against phosphorylcholinePrevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or…Athera Biotechnologies, ABDesignated
May 10, 2012Sirolimus in an implantable collagen matrixPrevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing…SiraNex Bio, LLCDesignated
May 15, 2009TenecteplaseRestore function to hemodialysis cathetersGenentech, Inc.Designated
Apr 3, 2009VonapanitasePrevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving…Proteon Therapeutics, Inc.Designated
Nov 4, 2003Tin ethyl etiopurpurinPrevention of access graft disease in hemodialysis patientsMiravant Medical TechnologiesDesignated
Oct 29, 1984EpoprostenolReplacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.Upjohn CompanyDesignated
Mar 29, 1984EpoprostenolReplacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrageGlaxo Wellcome Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.